Fennec Pharmaceuticals Inc.FENCNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

7 analysts·Limited coverage

100%

Rating Distribution

Strong Buy

00%

Buy

7100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 104% higher.

Bear Case

$14.00

+78%

Consensus

$16.00

+104%

Bull Case

$18.00

+129%

Price Range7 analysts

Low

Consensus

High

$14.00

$18.00

Current Target

Current Price

$7.86

Upside to Target

$8.14

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.59(4 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+41.58%

EPS+111.46%

FY2028

Rev+39.65%

EPS+66.49%

FY2029

Rev+25.33%

EPS+39.26%

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-72.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 8, 2026Piper Sandler

Fennec initiated with an Overweight at Piper Sandler

Target:$18.00

+137.5%from $7.58

Aug 15, 2025Craig-Hallum

Fennec price target raised to $14 from $13 at Craig-Hallum

Target:$14.00

+63.9%from $8.54

May 15, 2024Craig-Hallum

Fennec price target lowered to $17 from $20 at Craig-Hallum

Target:$17.00

+131.6%from $7.34

May 15, 2024H.C. Wainwright

Fennec Pharmaceuticals Inc. (FENC) PT Lowered to $15 at H.C. Wainwright

Target:$15.00

+113.4%from $7.03

Apr 4, 2024H.C. Wainwright

Fennec price target raised to $18 from $17 at H.C. Wainwright

Target:$18.00

+67.1%from $10.77

Mar 19, 2024Craig-Hallum

Fennec Pharmaceuticals Inc. (FENC) PT Raised to $18 at Craig-Hallum

Target:$18.00

+63.5%from $11.01

Nov 22, 2022Cantor Fitzgerald

Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight, Raises Price Target to $12

Target:$12.00

+30.9%from $9.17

Sep 26, 2022Wedbush

Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $19

Target:$19.00

+167.2%from $7.11

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance